Document:

EX-4.4

 Exhibit 4.4 

VOTING AGREEMENT 
 THIS
VOTING AGREEMENT (this “Agreement”) is made and entered into as of this 13th day of July, 2020, by and among BioAtla, Inc., a Delaware corporation (the “Company”), each holder of the Company’s Series D
Preferred Stock, $0.0001 par value per share (“Series D Preferred Stock”) (also referred to herein as the “Preferred Stock”), listed on Schedule A (together with any subsequent investors, or transferees, who
become parties hereto as “Investors” pursuant to Subsections 6.1(a) or 6.2 below, the “Investors”) and Himalaya Parent LLC, a Delaware limited liability company (“Himalaya”) and those certain
indirect beneficial owners of the Company’s Common Stock, $0.0001 par value per share (“Common Stock”) listed on Schedule B (together with any subsequent stockholders or option holders, or any transferees, who become
parties hereto as “Key Holders” pursuant to Subsections 6.1(b) or 6.2 below, the “Key Holders”, and together collectively with the Investors, the “Stockholders”). 

RECITALS 
 A. Concurrently
with the execution of this Agreement, the Company and the Investors are entering into a Series D Preferred Stock Purchase Agreement (as amended from time to time, the “Purchase Agreement”) providing for the sale of shares of Series
D Preferred Stock by the Company and in connection with that agreement the parties desire to provide the Investors with the right, among other rights, to designate the election of certain members of the board of directors of the Company (the
“Board”) in accordance with the terms of this Agreement. 
 B. The Certificate of Incorporation of the Company (the
“Certificate of Incorporation”) provides that (a) the holders of record of the shares of the Company’s Series D Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3) directors of
the Company; and (b) the holders of record of the Company’s Common Stock and of any other class or series of voting stock (including the Series D Preferred Stock), voting together as a single class on an
as-converted basis, shall be entitled to elect the balance of the total number of directors of the Company. 

C. The parties desire to enter into this Agreement to set forth their agreements and understandings with respect to how shares of the
Company’s capital stock held by them will be voted. 
 NOW, THEREFORE, the parties agree as follows: 

1. Voting Provisions Regarding Board of Directors. 

1.1. Size of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares (as defined below) owned by such Stockholder,
or over which such Stockholder has voting control or the right to direct voting, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and remain at seven (7) directors.
For purposes of this Agreement, the term “Shares” shall mean and include any securities of the Company the holders of which are entitled to vote for members of the Board, including without limitation, all shares of Common Stock and
Series D Preferred Stock by whatever name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise. 

  
 1 

 1.2. Board Composition. Each Stockholder agrees to vote, or cause to be voted, all
Shares owned by such Stockholder, or over which such Stockholder has voting control or the right to direct voting, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of
stockholders at which an election of directors is held or pursuant to any written consent of the stockholders, the following persons shall be elected to the Board: 

(a) One (1) person designated by Soleus Private Equity Fund I, L.P. (“Soleus”), which individual shall initially be Guy
Levy (the “Soleus Designee”), for so long as Soleus and its Affiliates continue to own beneficially at least twenty-five percent (25%) of the shares of Common Stock (including shares of Common Stock issued or issuable upon
conversion of Preferred Stock) purchased by Soleus as of the date hereof, which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like. 

(b) One (1) person designated by HBM Healthcare Investments (Cayman) Ltd. (“HBM”), which individual shall initially be
Dr. Priyanka Belawat (the “HBM Designee”), for so long as HBM and its Affiliates continue to own beneficially at least twenty-five percent (25%) of the shares of Common Stock (including shares of Common Stock issued or issuable
upon conversion of Preferred Stock) purchased by HBM as of the date hereof, which number is subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like. 

(c) One (1) person to be designated by the holders of a majority of the Series D Preferred Stock after the Initial Closing (as defined
in the Purchase Agreement), (the “Series D Designee” and collectively with the Soleus Designee and the HBM Designee, the “Series D Designees”), for so long as at least 25% of the shares of Series D Preferred Stock
outstanding as of the date hereof (subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like) remain outstanding. 

(d) Scott Smith, for so long as Scott Smith remains an officer of the Company. 

(e) Jay Short, for so long as Jay Short remains an officer or Chairman of the Company. 

(f) One (1) person who previously served on the board of managers of the Company’s predecessor, BioAtla, LLC, a Delaware limited
liability company, as designated by Jay Short, which individual shall initially be Lawrence Steinman (the “Legacy Designee”), provided, that if the Legacy Designee is no longer serving as a director, any replacement of the
Legacy Designee (which replacement shall not be required to have previously served on the board of managers of BioAtla, LLC) must be approved by two (2) of the three (3) Series D Designees, and provided further, that if two
(2) of the three (3) Series D Designees do not so approve or affirmatively disapprove of any Legacy Designee within thirty (30) days after notice of such Legacy Designee’s nomination, the Legacy Designee shall be designated by
Jay Short without any approval by the Series D Designees. 

 (g) One (1) person who is mutually acceptable to Jay Short and at least two
(2) of the three (3) Series D Designees, which designation shall be unfilled as of the date hereof. 
 To the extent that any of
clauses (a) through (g) above shall not be applicable, any member of the Board who would otherwise have been designated in accordance with the terms thereof shall instead be voted upon by all the Stockholders of the Company entitled to vote
thereon in accordance with, and pursuant to, the Certificate of Incorporation. 
 For purposes of this Agreement, an individual, firm,
corporation, partnership, association, limited liability company, trust or any other entity (collectively, a “Person”) shall be deemed an “Affiliate” of another Person who, directly or indirectly, controls, is
controlled by, or is under common control with, such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any limited liability company, limited partnership, investment fund or
registered investment company now or hereafter existing that is controlled by one or more general partners, managers, managing members or investment advisors of, or shares the same management company or investment advisor with, such Person; any
wholly-owned subsidiary of such Person; or any direct or indirect wholly-owned subsidiary of the ultimate parent entity of such Person; provided, however, that (i) each Janus Investor shall be deemed to be an
“Affiliate” of each other Janus Investor, and (ii) an entity that is an “Affiliate” of a Janus Investor (other than pursuant to the foregoing subpart (i)) shall not be deemed to be an “Affiliate” of any other Janus
Investor unless such entity is a Janus Investor (and, for the avoidance of doubt, an “Affiliate” of such entity shall not be deemed an “Affiliate” of any Janus Investor solely by virtue of being an “Affiliate” of such
entity). For the purposes of this Agreement, the term “Janus Investors” shall mean Investors, or permitted transferees of Shares held by Janus Investors, that are advisory or subadvisory clients of Janus Capital Management LLC,
including, but not limited to, Janus Henderson Global Life Sciences Fund, Janus Henderson Capital Funds Plc—Janus Henderson Global Life Sciences Fund, and Janus Henderson Biotech Innovation Master Fund Limited. 

1.3. Failure to Designate a Board Member. In the absence of any designation from the Persons or groups with the right to designate a
director as specified above, the director previously designated by them and then serving shall be re-elected if still eligible to serve as provided herein. 

1.4. Removal of Board Members. Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or
over which such Stockholder has voting control or the right to direct voting, from time to time and at all times, in whatever manner as shall be necessary to ensure that: 

(a) no director elected pursuant to Subsections 1.2 or 1.3 of this Agreement may be removed from office other
than for cause unless (i) such removal is directed or approved by the affirmative vote of the Person entitled under Subsection 1.2 to designate that director, or (ii) the Person(s) originally entitled to designate
or approve such director or occupy such Board seat pursuant to Subsection 1.2 is no longer so entitled to designate or approve such director or occupy such Board seat; 

 (b) any vacancies created by the resignation, removal or death of a director elected
pursuant to Subsections 1.2 or 1.3 shall be filled pursuant to the provisions of this Section 1; and 

(c) upon the request of any party entitled to designate a director as provided in Subsections 1.2(a) through
(e) to remove such director, such director shall be removed. 
 All Stockholders agree to execute any written consents required to perform the
obligations of this Agreement, and the Company agrees at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of electing directors. 

1.5. No Liability for Election of Recommended Directors. No Stockholder, nor any Affiliate of any Stockholder, shall have any liability
as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Stockholder have any liability as a result of voting for any such
designee in accordance with the provisions of this Agreement. 
 2. Vote to Increase Authorized Common Stock. Each Stockholder
agrees to vote or cause to be voted all Shares owned by such Stockholder, or over which such Stockholder has voting control or the right to direct voting, from time to time and at all times, in whatever manner as shall be necessary to
(a) increase the number of authorized shares of Preferred Stock from time to time to ensure that there will be sufficient shares of Preferred Stock necessary for issuances of any Pre-IPO Make-Whole Shares
that may be required to be issued to the Purchasers (as such terms are defined in the Purchase Agreement) from time to time pursuant to the Purchase Agreement and (b) increase the number of authorized shares of Common Stock from time to time to
ensure that there will be sufficient shares of Common Stock (i) available for conversion of all of the shares of Preferred Stock outstanding at any given time and (ii) necessary for issuances of any
Post-IPO Make-Whole Shares (as such term is defined in the Purchase Agreement) that may be required to be issued to the Purchasers from time to time pursuant to the Purchase Agreement. 

3. Drag-Along Right. 

3.1. Definitions. A “Sale of the Company” shall mean either: (a) a transaction or series of related transactions
in which a Person, or a group of related Persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a “Stock Sale”); or (b) a transaction
that qualifies as a “Deemed Liquidation Event” as defined in the Certificate of Incorporation. 
 3.2. Actions to be
Taken. In the event that (i) the holders of a majority of the Series D Preferred Stock, voting separately (the “Selling Investors”), and (ii) a majority of the Board, which majority must include the affirmative vote of
at least two (2) of the three (3) Series D Designees, approve a Sale of the Company in writing, specifying that this Section 3 shall apply to such transaction, then each Stockholder and the Company hereby agree:

 (a) if such transaction requires stockholder approval, with respect to all Shares that such Stockholder owns or over which such
Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Sale of the Company (together with any related amendment or restatement to the
Certificate of Incorporation required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Sale of
the Company; 

 (b) if such transaction is a Stock Sale, to sell the same proportion of shares of capital
stock of the Company beneficially held by such Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares, and, except as permitted in Subsection 3.3 below, on the same terms
and conditions as the Selling Investors; 
 (c) to execute and deliver all related documentation and take such other action in support of
the Sale of the Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 3, including, without limitation, executing and delivering
instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens,
claims and encumbrances) and any similar or related documents; 
 (d) not to deposit, and to cause their Affiliates not to deposit, except
as provided in this Agreement, any Shares of the Company owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by
the acquiror in connection with the Sale of the Company; 
 (e) to refrain from exercising any dissenters’ rights or rights of
appraisal under applicable law at any time with respect to such Sale of the Company; 
 (f) if the consideration to be paid in exchange for
the Shares pursuant to this Section 3 includes any securities and due receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities or of any Person as a
broker or dealer or agent with respect to such securities or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited
investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares
which would have otherwise been sold by such Stockholder, an amount in cash equal to the fair value (as determined in good faith by the Board) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such
securities in exchange for the Shares; and 
 (g) in the event that the Selling Investors, in connection with such Sale of the Company,
appoint a stockholder representative (the “Stockholder Representative”) with respect to matters affecting the Stockholders under the applicable definitive transaction agreements following consummation of such Sale of the Company,
(x) to consent to (i) the appointment of such Stockholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the
payment of such Stockholder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s
services and duties in connection with such Sale of the 

 
Company and its related service as the representative of the Stockholders, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other
Stockholder with respect to any action or inaction taken or failed to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct. 

3.3. Exceptions. Notwithstanding the foregoing, a Stockholder will be required to comply with Subsection 3.2 above in connection
with any proposed Sale of the Company (the “Proposed Sale”) only if: 
 (a) any representations and warranties to be made
by such Stockholder in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that
(i) the Stockholder holds all right, title and interest in and to the Shares such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Stockholder in connection with the transaction have
been duly authorized, if applicable, (iii) the documents to be entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable (subject to customary limitations) against the
Stockholder in accordance with their respective terms and (iv) neither the execution and delivery of documents to be entered into by the Stockholder in connection with the transaction, nor the performance of the Stockholder’s obligations
thereunder, will cause a breach or violation of the terms of any agreement to which the Stockholder is a party, or any law or judgment, order or decree of any court or governmental agency that applies to the Stockholder; 

(b) the Stockholder shall not be liable for the inaccuracy or breach of any representation or warranty made by any other Person in connection
with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any of
identical representations, warranties and covenants provided by all stockholders); 
 (c) the liability for indemnification, if any, of
such Stockholder in the Proposed Sale and for the inaccuracy of any representations and warranties made by the Company or its Stockholders in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent
that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all
stockholders), and is pro rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such Proposed Sale; 

(d) liability shall be limited to such Stockholder’s applicable share (determined based on the respective proceeds payable to each
Stockholder in connection with such Proposed Sale in accordance with the provisions of the Certificate of Incorporation) of a negotiated aggregate indemnification amount that applies equally to all Stockholders but that in no event exceeds the
amount of consideration otherwise payable to such Stockholder in connection with such Proposed Sale, except with respect to claims related to fraud by such Stockholder, the liability for which need not be limited as to such Stockholder; 

 (e) upon the consummation of the Proposed Sale, (i) each holder of each class or
series of capital stock of the Company will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock and if any holders of any
capital stock of the Company are given a choice as to the form of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be given the same option, (ii) each holder of a series of Preferred Stock
will receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series, (iii) each holder of Common Stock will receive the same amount of
consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (iv) unless the holders of at least a majority of the Preferred Stock voting together as a single class on an as-converted basis, elect to receive a lesser amount by written notice given to the Company at least ten (10) days prior to the effective date of any such Proposed Sale, the aggregate consideration receivable
by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock
and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Company’s Certificate of Incorporation in effect immediately
prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration to be paid in exchange for the Key Holder’s Shares or Investor’s Shares, as applicable, pursuant to this Subsection
3.3(e) includes any securities and due receipt thereof by any Key Holder or Investor would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to
such securities or (y) the provision to any Key Holder or Investor of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in
Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Key Holder or Investor in lieu thereof, against surrender of the Key Holder’s Shares or Investor’s Shares, as applicable, which would have
otherwise been sold by such Key Holder or Investor, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Key Holder or Investor would otherwise receive as of the date of the issuance of
such securities in exchange for the Key Holder Shares or Investor’s Shares, as applicable; 
 (f) subject to clause (e) above,
requiring the same form of consideration to be available to the holders of any single class or series of capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received
as a result of the Proposed Sale, all holders of such capital stock will be given the same option; provided, however, that nothing in this Subsection 3.3(f) shall entitle any holder to receive any form of consideration that such holder
would be ineligible to receive as a result of such holder’s failure to satisfy any condition, requirement or limitation that is generally applicable to the Company’s stockholders; 

(g) with respect to any Stockholder who is not an officer or employee of the Company, such Stockholder is not required to (i) agree to
any covenant not to compete, exclusivity covenant, covenant not to solicit or similar restrictive covenant or (ii) execute a general release (other than a release limited to claims solely in the Stockholder’s capacity as a holder of shares
of capital stock of the Company), in connection with the Proposed Sale; 

 (h) in connection with the Proposed Sale such Stockholder and its Affiliates are not
required to extend or terminate any contractual or other relationship with the Company, the acquirer, or their respective Affiliates, except that the Stockholder may be required to agree to terminate the investment-related documents between or among
such Stockholder, that Company, and/or other stockholders of the Company; 
 (i) such Stockholder shall not be obligated to make any out-of-pocket expenditures prior to the consummation of the Proposed Sale (excluding modest expenditures for postage, copies, etc.) or to pay any expenses incurred in
connection with the consummation of the Proposed Sale, except indirectly to the extent such costs are incurred for the benefit of all of the Company’s stockholders and are paid by the Company or the acquiring party; provided, that costs
incurred by or on behalf of any Stockholder for its sole benefit will not be considered costs of the transaction thereunder; and 
 (j) the
agreement and plan of merger or similar or related document governing the Proposed Sale (together, the “Merger Agreement”) will, by its terms, prohibit any amendment to be made to the terms of the Merger Agreement that are contrary
to the conditions set forth in this Section 3 after the Merger Agreement has been executed or adopted by a vote or written consent of the stockholders of the Company. 

3.4. Restrictions on Sales of Control of the Company. No Stockholder shall be a party to any Stock Sale unless (a) all holders of
Preferred Stock are allowed to participate in such transaction(s) and (b) the consideration received pursuant to such transaction is allocated among the parties thereto in the manner specified in the Certificate of Incorporation in effect
immediately prior to the Stock Sale (as if such transaction(s) were a Deemed Liquidation Event), unless the holders of at least the requisite percentage required to waive treatment of the transaction(s) as a Deemed Liquidation Event pursuant to the
terms of the Certificate of Incorporation elect to allocate the consideration differently by written notice given to the Company at least 10 days prior to the effective date of any such transaction or series of related transactions. 

4. Remedies. 
 4.1.
Covenants of the Company. The Company agrees to use its best efforts, within the requirements of applicable law, to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement.
Such actions include, without limitation, the use of the Company’s best efforts to cause the nomination and election of the directors as provided in this Agreement. 

4.2. Irrevocable Proxy and Power of Attorney. Each party to this Agreement hereby constitutes and appoints as the proxies of the party
and hereby grants a power of attorney to the Chief Executive Officer and the President of the Company, with respect to the matters set forth in Subsection 1.2(a) through (g), the party entitled to designate the director in question and
a designee of the Selling Investors, and each of them, with full power of substitution, with respect to the matters set forth herein, including without limitation, election of persons as members of the Board in accordance with
Section 1 hereto, votes to increase authorized shares pursuant to Section 2 hereof and votes regarding any Sale of the Company pursuant to Section 3 hereof, and hereby
authorizes each of them to represent and to vote, if and only if the party (i) fails to vote or (ii) attempts to vote (whether by proxy, in person or by written consent), in a manner which is

 
inconsistent with the terms of this Agreement, all of such party’s Shares in favor of the election of persons as members of the Board determined pursuant to and in accordance with
Section 1 of this Agreement or the increase of authorized shares or approval of any Sale of the Company pursuant to and in accordance with the terms and provisions of Sections 2 and 3, respectively, of this
Agreement or to take any action necessary to effect Sections 2 and 3, respectively, of this Agreement. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is given in consideration of the
agreements and covenants of the Company and the parties in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless and until this Agreement terminates or expires
pursuant to Section 5 hereof. Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Agreement terminates or expires
pursuant to Section 5 hereof, purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other than this Agreement),
arrangement or understanding with any person, directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the Shares, in each case, with respect to any of the matters set forth herein. 

4.3. Specific Enforcement. Each party acknowledges and agrees that each party hereto will be irreparably damaged in the event any of
the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that each of the Company and the Stockholders shall be entitled to an injunction to
prevent breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United States or any state having subject matter jurisdiction. 

4.4. Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative. 
 5. Term. This Agreement shall be effective as of the date hereof and shall continue in effect until and shall
terminate upon the earliest to occur of (a) the consummation of the Company’s first underwritten public offering of its Common Stock (other than a registration statement relating either to the sale of securities to employees of the Company
pursuant to its stock option, stock purchase or similar plan or an SEC Rule 145 transaction); (b) the consummation of a Sale of the Company, other than an Asset Sale (as defined in the Certificate of Incorporation), and distribution of proceeds to
the Stockholders in accordance with the Certificate of Incorporation; provided that the provisions of Section 3 hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the
provisions of Section 3 with respect to such Sale of the Company; and (c) termination of this Agreement in accordance with Subsection 6.8 below. 

6. Miscellaneous. 
 6.1.
Additional Parties. 
 (a) Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
Preferred Stock to a purchaser who is not already an Investor hereunder after the date hereof, as a condition to the issuance of such shares, the Company shall require that any such purchaser become a party to this Agreement by executing and
delivering (i) 

 
the Adoption Agreement attached to this Agreement as Exhibit A, or (ii) a counterpart signature page hereto agreeing to be bound by and subject to the terms of this Agreement as an
Investor and Stockholder hereunder. In either event, each such person thereafter shall be deemed an Investor and Stockholder for all purposes under this Agreement. 

(b) In the event that after the date of this Agreement, the Company enters into an agreement with any Person to issue shares of capital stock
to such Person (other than to a purchaser of Preferred Stock described in Subsection 6.1(a) above), following which such Person shall hold Shares constituting one percent (1%) or more of the Company’s then outstanding capital stock
(treating for this purpose all shares of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible securities, as if exercised and/or converted or exchanged), then the Company shall cause such Person, as a
condition precedent to entering into such agreement, to become a party to this Agreement by executing an Adoption Agreement in the form attached hereto as Exhibit A, agreeing to be bound by and subject to the terms of this Agreement as a
Stockholder and thereafter such person shall be deemed a Stockholder for all purposes under this Agreement. 
 6.2. Transfers. Each
transferee or assignee of any Shares subject to this Agreement shall continue to be subject to the terms hereof, and, as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall agree in writing to be
subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any transferee, such
transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee’s signature appeared on the signature pages of this Agreement and shall be deemed to be an Investor and Stockholder, or Key Holder and
Stockholder, as applicable. The Company shall not permit the transfer of the Shares subject to this Agreement on its books or issue a new certificate representing any such Shares unless and until such transferee shall have complied with the terms of
this Subsection 6.2. Each certificate, instrument, or book entry representing the Shares subject to this Agreement if issued on or after the date of this Agreement shall be notated by the Company with the legend set forth in
Subsection 6.12. 
 6.3. Successors and Assigns. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors, assigns, heirs, executors, administrators and other legal representatives of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors, assigns, heirs, executors, administrators and other legal representatives any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement. The rights of any Investor under this Agreement may be assigned, in whole or in part, to any Affiliate in connection with the transfer of the related Shares by such Investor to such Affiliate. 

6.4. Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed
in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, without
regard to its principles of conflicts of laws. 

 6.5. Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.6. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. 
 6.7. Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business
hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or
(d) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the
respective parties at their address as set forth on the signature pages, or to such email address, facsimile number or address as subsequently modified by written notice given in accordance with this Subsection 6.7. If notice is given to the
Company, a copy shall also be sent to Dechert LLP, 1900 K Street NW, Washington, DC 20006, Attn: David E. Schulman and if notice is given to Stockholders, a copy, which shall not constitute notice, shall also be given to such counsel as may appear
with such Investor’s address on the signature pages attached to the Purchase Agreement. 
 Notwithstanding any of the foregoing, with respect to HBM
Healthcare Investments (Cayman) Ltd., only a nationally recognized courier service (such as FedEx or DHL) shall be used to effectuate the delivery of any notices pursuant to this Subsection 6.7, and such notice or other communication for
purpose of this Agreement shall not be treated as effective or having been given if some other delivery method is utilized; provided, however, that if such notice is being sent internationally, it shall not be deemed defective if such
courier does not deliver such notice on the next business day following deposit (provided that such notice shall be deemed delivered on the date of delivery by such courier service), and provided further, that HBM may agree to receive
notice in some other manner set forth in this Subsection 6.7 by written election; and a copy (which shall not constitute notice) shall also be sent to Sidley Austin LLP, 1999 Avenue of the Stars, 17th Floor, Los Angeles, California 90067,
Attention: Mehdi Khodadad. 
 6.8. Consent Required to Amend, Modify, Terminate or Waive. This Agreement may be amended, modified or
terminated and the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company; (b) the Key Holders holding a
majority of the shares of Common Stock then held by the Key Holders; and (c) the holders of at least a majority of the shares of Common Stock issued or issuable upon conversion of the shares of Preferred Stock held by the Investors
(voting as a single class and on an as-converted basis). Notwithstanding the foregoing: 

 (a) this Agreement may not be amended, modified or terminated and the observance of any
term of this Agreement may not be waived with respect to any Investor or Key Holder without the written consent of such Investor or Key Holder, unless such amendment, modification, termination or waiver applies to all Investors or Key Holders, as
the case may be, in the same fashion; 
 (b) the consent of the Key Holders shall not be required for any amendment, modification,
termination or waiver if such amendment, modification, termination or waiver either (i) is not directly applicable to the rights of the Key Holders hereunder or (ii) does not adversely affect the rights of the Key Holders in a manner that
is different than the effect on the rights of the other parties herein; 
 (c) Schedule A hereto may be amended by the Company from
time to time in accordance with the Purchase Agreement to add information regarding Additional Purchasers (as defined in the Purchase Agreement) without the consent of the other parties hereto; 

(d) any provision hereof may be waived by the waiving party on such party’s own behalf, without the consent of any other party; 

(e) Subsection 1.2(a) of this Agreement and this Subsection 6.8(e) shall not be amended, modified, terminated or waived without
the written consent of Soleus; 
 (f) Subsection 1.2(b) of this Agreement and this Subsection 6.8(f) shall not be amended,
modified, terminated or waived without the written consent of HBM; 
 (g) Subsection 1.2(c) of this Agreement and this Subsection
6.8(g) shall not be amended, modified, terminated or waived without the written consent of the holders of at least a majority of the shares of Common Stock issued or issuable upon conversion of the shares of Preferred Stock held by the Investors
(voting as a single class and on an as-converted basis); 
 (h) Subsection 1.2(d),
(e), (f) and (g) of this Agreement and this Subsection 6.8(h) shall not be amended, modified, terminated or waived without the written consent of the Key Holders holding a majority of the shares of Common Stock then
held by Key Holders who are at such time providing services to the Company as an officer, director, employee or consultant; and 
 (i)
Notwithstanding Subsection 6.8(a) of this Agreement, neither Subsection 3.3 of this Agreement nor any subsection thereof shall be amended, modified, terminated or waived as it applies to any Investor without the written consent of
(i) the holders of the majority of shares held by such affected Investors, including Soleus so long as Soleus holds any Shares and HBM so long as HBM holds any Shares, and the Janus Investors so long as the Janus Investors hold any Shares,
(ii) the holders of a majority of shares held by the Key Holders, and (iii) solely with respect to Subsections 3.3(g)—(i) and this Subsection 6.8(i) of this Agreement, such Subsections shall not be amended,
modified, terminated or waived without the written consent of Pfizer Venture (US) LLC; and 
 (j) None of the definition of
“Affiliate” (as it pertains to the Janus Investors), the definition of “Janus Investors”, or this Section 6.8(j) of this Agreement shall be amended, modified, terminated or waived in a manner that would
be adverse to the Janus Investors without the prior written consent of the Janus Investors. 

 The Company shall give prompt written notice of any amendment, modification, termination,
or waiver hereunder to any party that did not consent in writing thereto. Any amendment, modification, termination or waiver effected in accordance with this Subsection 6.8 shall be binding on each party and all of such party’s
successors and permitted assigns, whether or not any such party, successor or assignee entered into or approved such amendment, termination or waiver. For purposes of this Subsection 6.8, the requirement of a written instrument may be
satisfied in the form of an action by written consent of the Stockholders circulated by the Company and executed by the Stockholder parties specified, whether or not such action by written consent makes explicit reference to the terms of this
Agreement. 
 6.9. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this
Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party
nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other
breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 6.10. Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. 
 6.11. Entire Agreement. This Agreement (including the Exhibits hereto), the Certificate of
Incorporation and the other Transaction Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral
agreement relating to the subject matter hereof existing between the parties is expressly canceled. 
 6.12. Legend on Share
Certificates. Each certificate, instrument, or book entry representing any Shares issued after the date hereof shall be notated by the Company with a legend reading substantially as follows: 

“THE SHARES REPRESENTED HEREBY ARE SUBJECT TO A VOTING AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY OF WHICH MAY BE OBTAINED
UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT VOTING AGREEMENT, INCLUDING CERTAIN RESTRICTIONS
ON TRANSFER AND OWNERSHIP SET FORTH THEREIN.” 

 The Company, by its execution of this Agreement, agrees that it will cause the certificates evidencing the
Shares issued after the date hereof to be notated with the legend required by this Subsection 6.12 of this Agreement, and it shall supply, free of charge, a copy of this Agreement to any holder of such Shares upon written request from such
holder to the Company at its principal office. The parties to this Agreement do hereby agree that the failure to cause the certificates, instruments, or book entry evidencing the Shares to be notated with the legend required by this Subsection
6.12 herein and/or the failure of the Company to supply, free of charge, a copy of this Agreement as provided hereunder shall not affect the validity or enforcement of this Agreement. 

6.13. Stock Splits, Stock Dividends, etc. In the event of any issuance of Shares of the Company’s voting securities hereafter to
any of the Stockholders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall become subject to this Agreement and shall be notated with the legend set
forth in Subsection 6.12. 
 6.14. Manner of Voting. The voting of Shares pursuant to this Agreement may be effected in
person, by proxy, by written consent or in any other manner permitted by applicable law. For the avoidance of doubt, voting of the Shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement. 

6.15. Further Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and
at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions
contemplated hereby and to otherwise carry out the intent of the parties hereunder. 
 6.16. Dispute Resolution. The parties
(a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for
the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject
matter hereof may not be enforced in or by such court. 
 6.17. WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A
JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT 

 
BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.18. Costs of Enforcement. If any party to
this Agreement seeks to enforce its rights under this Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation,
all reasonable attorneys’ fees. 
 6.19. Aggregation of Stock. All Shares held or acquired by a Stockholder and/or its
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement, and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.20. Spousal Consent. If any individual Stockholder is married on the date of this Agreement, such Stockholder’s spouse shall
execute and deliver to the Company a consent of spouse in the form of Exhibit B hereto (“Consent of Spouse”), effective on the date hereof. Notwithstanding the execution and delivery thereof, such consent shall not be deemed
to confer or convey to the spouse any rights in such Stockholder’s Shares that do not otherwise exist by operation of law or the agreement of the parties. If any individual Stockholder should marry or remarry subsequent to the date of this
Agreement, such Stockholder shall within thirty (30) days thereafter obtain his/her new spouse’s acknowledgement of and consent to the existence and binding effect of all restrictions contained in this Agreement by causing such spouse to
execute and deliver a Consent of Spouse acknowledging the restrictions and obligations contained in this Agreement and agreeing and consenting to the same. 

6.21. Other Business Activities of Investors. The Company hereby agrees and acknowledges that the Investors (together with their
Affiliates) are in the business of venture capital and/or private equity investing, review the business plans and related proprietary information of, and invest in, many enterprises, including enterprises which may have products or services which
compete directly or indirectly with those of the Company (as currently conducted or as currently proposed to be conducted). Nothing in this Agreement or any other agreement related to the transactions contemplated by this Agreement (collectively,
the “Transaction Agreements”) shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise, whether or not such enterprise has products or services that compete with those of the
Company. Further, the Company, each Investor, and each Stockholder acknowledges and agrees that (i) certain of the Investors (or the Affiliates of such Investors) (each, a “Strategic Investor”) may presently have, or may engage
in the future in, internal development programs, or may receive information from third parties that relates to, and may develop and commercialize products independently or in cooperation with such third parties, that are similar to or that are
directly or indirectly competitive with, the Company’s development programs, products or services, and (ii) any employee of such Strategic Investor serving on the Board is serving in such capacity at the request, and for the benefit, of
the Company. Accordingly, such Strategic Investor’s designation of any individual to the Board (the “Board Designee”), the service of such Board Designee on the Board, or the exercise by such Strategic Investor of any rights
under this Agreement or any of the Transaction Agreements, shall not in any way preclude or restrict such 

 
Strategic Investor from conducting any development program, commercializing any product or service or otherwise engaging in any enterprise, whether or not such development program, product,
service or enterprise, competes with those of the Company, so long as such activities do not result in a violation of the confidentiality provisions of this Agreement or any other Transaction Agreement. Nothing herein or in any other Transaction
Agreement shall be construed to impose on such Strategic Investor or any Board Designee any restriction, duty or obligation other than as expressly set forth herein or therein. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties have executed this Voting Agreement as of the date first
written above. 
  

			
	BIOATLA, INC.
		
	By:	 	/s/ Jay Short
	Name:	 	Jay Short
	Title:	 	Chief Executive Officer
		
	Address:	 	11805 Torreyana Road
San Diego, CA 92121

 [Signature Page to Voting Agreement] 

 
			
	KEY HOLDERS:
	
	Jay Short, PhD
		
	By:	 	/s/ Jay Short
	Name:	 	Jay Short
	Title:	 	Chief Executive Officer
		
	Address:	 	11805 Torreyana Road
San Diego, CA 92121

 [Signature Page to Voting Agreement] 

 
			
	KEY HOLDERS:
	
	Carolyn Short
		
	By:	 	/s/ Carolyn Short
	Name:	 	Carolyn Short
		
	Address:	 	11805 Torreyana Road
San Diego, CA 92121

 [Signature Page to Voting Agreement] 

 
			
	KEY HOLDERS:
	
	Scott Smith
		
	By:	 	/s/ Scott Smith
	Name:	 	Scott Smith
		
	Address:	 	11805 Torreyana Road
San Diego, CA 92121

 [Signature Page to Voting Agreement] 

 
			
	KEY HOLDERS:
	
	HIMALAYA PARENT LLC
		
	By:	 	/s/ Jay Short
	Name:	 	Jay Short
	Title:	 	Chief Executive Officer
		
	Address:	 	11805 Torreyana Road
		 	San Diego, CA 92121

 [Signature Page to Voting Agreement] 

 
			
	KEY HOLDERS:
	
	BIOTECH INVESTMENT GROUP,
LLC
		
	By:	 	/s/ Masood Tayebi
	Name:	 	Masood Tayebi
	Title:	 	Managing Member
		
	Address:	 	7310 Miramar Road Suite 500
		 	San Diego, CA 92126

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	SOLEUS PRIVATE EQUITY FUND I,
L.P.
	
	By: Soleus Private Equity GP I, LLC, its
General Partner
		
	By:	 	/s/ Steven Musumeci
	Name:	 	Steven Musumeci
	Title:	 	Chief Operating Officer
		
	Address:	 	Soleus Private Equity Fund I, L.P.
		 	104 Field Point Road, Second
		 	Floor
		 	Greenwich, CT 06830

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	HBM HEALTHCARE INVESTMENTS
(CAYMAN) LTD.
		
	By:	 	/s/ Jean-Marc LeSieur
	Name:	 	Jean-Marc LeSieur
	Title:	 	Director
		
	Address:	 	Governors Square, Suite #4-212-2
		 	23 Lime Tree Bay Avenue
		 	West Bay
		 	Grand Cayman, Cayman Islands

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	ZONE II HEALTHCARE HOLDINGS,
LLC
	
	By: Farallon Capital Management, L.L.C.,
its Manager
		
	By:	 	/s/ Philip Dreyfuss
	Name:	 	Philip Dreyfuss
	Title:	 	Managing Member
		
	Address:	 	c/o Farallon Capital Management,
		 	L.L.C.
		 	One Maritime Plaza, Suite 2100
		 	San Francisco, CA 94111
		 	Attn: Philip Dreyfuss
		 	Email:
		 	pdreyfuss@faralloncapital.com
		 	And
		 	Email:
		 	generalcounsel@faralloncapital.com

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	CORMORANT GLOBAL
HEALTHCARE MASTER FUND, LP
	
	By: Cormorant Global Healthcare GP, LLC
		
	By:	 	/s/ Bihua Chen
	Name:	 	Bihua Chen
	Title:	 	Managing Member of the GP
		
	Address:	 	200 Clarendon Street, 52nd Floor
		 	Boston, MA 02116

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	CORMORANT PRIVATE
HEALTHCARE FUND II, LP
	
	By: Cormorant Private Healthcare GP II,
LLC
		
	By:	 	/s/ Bihua Chen
	Name:	 	Bihua Chen
	Title:	 	Managing Member of the GP
		
	Address:	 	200 Clarendon Street, 52nd Floor
		 	Boston, MA 02116

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	667, L.P.
	
	By: BAKER BROS. ADVISORS LP,
management company and investment
advisor to 667, L.P., pursuant to authority
granted to it by Baker Biotech Capital, L.P.,
general partner to 667, L.P., and not as the
general
partner.
		
	By:	 	/s/ Scott Lessing
	Name:	 	Scott Lessing
	Title:	 	President
		
	Address:	 	860 Washington St, 3rd Floor
		 	New York, NY 10014

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	BAKER BROTHERS LIFE SCIENCES,
L.P.
	
	By: BAKER BROS. ADVISORS LP,
management company and investment
advisor to Baker Brothers Life Sciences,
L.P., pursuant to authority granted to it by
Baker Brothers Life Sciences Capital, L.P.,
general
partner to Baker Brothers Life
Sciences, L.P., and not as the general
partner.
		
	By:	 	/s/ Scott Lessing
	Name:	 	Scott Lessing
	Title:	 	President
		
	Address:	 	860 Washington St, 3rd Floor
		 	New York, NY 10014

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	A.M. PAPPAS LIFE SCIENCE VENTURES V, LP
		
	 By:
	 	AMP&A Management V, LLC, its General Partner

 

			
	By:	 	/s/ Arthur M. Pappas

 
			
	Name:	 	Arthur M. Pappas
	Title:	 	CEO & Managing Partner

  

			
	Address:	 	 c/o Matthew Boyer

		 	Pappas Capital, LLC
		 	2520 Meridian Parkway, Suite 400
		 	Durham, NC 27713
		 	mboyer@pappas-capital.com
		 	(919) 998-3300

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	PV V CE FUND, LP
		
	 By:
	 	AMP&A Management V, LLC, its General Partner

 

			
	By:	 	/s/ Arthur M. Pappas

 
			
	Name:	 	Arthur M. Pappas
	Title:	 	CEO & Managing Partner

  

			
	Address:	 	 c/o Matthew Boyer

		 	Pappas Capital, LLC
		 	2520 Meridian Parkway, Suite 400
		 	Durham, NC 27713
		 	mboyer@pappas-capital.com
		 	(919) 998-3300

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	 JANUS HENDERSON GLOBAL LIFE SCIENCES FUND

		
	 By:
	 	 Janus Capital Management LLC, its investment advisor

 

			
	By:	 	 /s/ Andrew Acker

			
	Name:	 	 Andrew Acker

	Title:	 	 Authorized Signatory 

 

			
	Address:	 	 c/o Janus Capital Management LLC

		 	 151 Detroit Street

		 	Denver, CO 80206
	
	 With a copy (which shall not constitute notice) to:

		 	 Perkins Coie LLP

		 	 3150 Porter Drive

		 	 Palo Alto, CA 94306

		 	 Attn: Adrian Rich

		 	 Email: arich@perkinscoie.com

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	 JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED FUND

		
	 By:
	 	 Janus Capital Management LLC, its investment advisor

 

			
	By:	 	 /s/ Andrew Acker

			
	Name:	 	 Andrew Acker

	Title:	 	 Authorized Signatory

 

			
	Address:	 	 c/o Janus Capital Management LLC

		 	 151 Detroit Street

		 	Denver, CO 80206
	
	 With a copy (which shall not constitute notice) to:

		 	 Perkins Coie LLP

		 	 3150 Porter Drive

		 	 Palo Alto, CA 94306

		 	 Attn: Adrian Rich

		 	Email: arich@perkinscoie.com

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	 JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES FUND 

		
	 By:
	 	 Janus Capital Management LLC, its investment advisor

 

			
	By:	 	 /s/ Andrew Acker

			
	Name:	 	 Andrew Acker

	Title:	 	 Authorized Signatory

 

			
	Address:	 	 c/o Janus Capital Management LLC

		 	 151 Detroit Street

		 	Denver, CO 80206
	
	 With a copy (which shall not constitute notice) to:

		 	 Perkins Coie LLP

		 	 3150 Porter Drive

		 	 Palo Alto, CA 94306

		 	 Attn: Adrian Rich

		 	 Email: arich@perkinscoie.com

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:

	
	BOXER CAPITAL, LLC
		
	By:	 	/s/ Aaron Davis

 
			
	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer
		
	Address:	 	11682 El Camino Real, Suite 320
		 	San Diego, CA 92130

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:

	
	 MVA INVESTORS, LLC

		
	By:	 	/s/ Aaron Davis

 
			
	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer
		
	Address:	 	11682 El Camino Real, Suite 320
		 	San Diego, CA 92130

 [Signature Page to Voting Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:

	
	 PFIZER VENTURES (US) LLC

		
	By:	 	 /s/ Barbara Dalton, Ph.D. 

			
	Name:	 	 Barbara Dalton, Ph. D.

	Title:	 	 President, Pfizer Ventures (US) LLC 

		
	Address:	 	 Andrew J. Muratore, Esq.

		 	 Pfizer Inc.

		 	 235 East 42nd Street

		 	 New York, NY 10017

 [Signature Page to Voting Agreement] 

 SCHEDULE B 

KEY HOLDERS 
  

	
	 Jay Short
  

	 Carolyn Short
  

	 Scott Smith
  

	 Biotech Investment Group, LLC
  

	 Himalaya Parent LLCEX-10.1

 Exhibit 10.1 

BIOATLA, INC. 
 2020
EQUITY INCENTIVE PLAN 
 Section 1. Purpose of the Plan. 

The purpose of the BioAtla, Inc. 2020 Equity Incentive Plan (the “Plan”) is to assist the Company and its Subsidiaries in
attracting and retaining valued Employees, Consultants and Non-Employee Directors by offering them a greater stake in the Company’s success and a closer identity with it, and to encourage ownership of the
Company’s shares by such Employees, Consultants and Non-Employee Directors. 
 Section 2. Definitions.

 As used herein, the following definitions shall apply: 

2.1. “Award” means the grant of Options, SARs, Restricted Stock, Restricted Stock Units, Performance Stock, Performance Stock
Units and Other Stock-Based Awards under the Plan. 
 2.2. “Award Agreement” means the written agreement, instrument or
document evidencing an Award. 
 2.3. “Board” means the Board of Directors of the Company. 

2.4. “Cause” means, 

(a) if the applicable Participant is party to an effective employment, consulting, severance or similar agreement with the Company or a
Subsidiary, and such term is defined therein, “Cause” shall have the meaning provided in such agreement; 
 (b) if the applicable
Participant is not a party to an effective employment, consulting, severance or similar agreement with the Company or a Subsidiary or if no definition of “Cause” is set forth in the applicable employment, consulting, severance or similar
agreement, “Cause” shall have the meaning provided in the applicable Award Agreement; 
 (c) if neither clause (a) nor clause
(b) applies, then “Cause” shall mean (i) engaging in (A) willful or gross misconduct or (B) willful or gross neglect; (ii) failing to follow the lawful directions of superiors or the Board or the written policies
and practices of the Company or any Subsidiary; (iii) the Participant’s indictment for, conviction of, plea of guilty or no contest to, or commission of, a felony or a crime involving any of the following: moral turpitude, dishonesty,
breach of trust or unethical business conduct; or the Participant’s indictment for, conviction of, plea of guilty or no contest to, or commission of, any crime involving the Company or any Subsidiary; (iv) fraud, misappropriation or
embezzlement; (v) a material breach of the Participant’s employment agreement (if any) with the Company or any Subsidiary, whether or not such breach results in the termination of the Participant’s employment; (vi) acts or
omissions constituting a material failure to perform substantially and adequately the duties assigned to the Participant that are consistent with his or her position(s); (vii) any illegal act detrimental to the

 
Company or any Subsidiary; (viii) repeated failure to devote substantially all of the Participant’s business time and efforts to the Company or any Subsidiary if required by the
Participant’s employment agreement; or (ix) the Participant’s abuse of illegal drugs or other controlled substances or the Participant’s habitual intoxication while providing services to the Company or any Subsidiary. 

A Participant’s resignation or death, in either case, at a time when Cause to terminate the Participant’s employment or other
service exists shall be treated as a termination for Cause for all purposes of the Plan and the Participant’s Awards and Award Agreements. 

2.5. “Change in Control” means, unless otherwise provided in an Award Agreement, after the Effective Date: 

(a) the acquisition in one or more transactions (whether by purchase, merger, amalgamation or otherwise) by any “Person” (as such
term is used for purposes of Section 13(d) or Section 14(d) of the Exchange Act, but excluding, for this purpose, (i) the Company and the Subsidiaries, (ii) any employee benefit plan of the Company or any Subsidiary or
(iii) an entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of shares of the Company) of “Beneficial Ownership” (within the meaning of Rule 13d-3 under the Exchange Act), of more than fifty percent (50%) of the combined voting power of the Company’s then outstanding voting securities (the “Voting Securities”); 

(b) a change in the composition of the Board such that the individuals who as of any date constitute the Board (the “Incumbent
Board”) cease to constitute a majority of the Board at any time during the 24-month period immediately following such date; provided, however, that if the election, or nomination for election by the
Company’s stockholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board, and provided further that any reductions in the size of
the Board that are instituted voluntarily by the Incumbent Board shall not constitute a Change in Control, and after any such reduction the “Incumbent Board” shall mean the Board as so reduced; 

(c) a complete liquidation or dissolution or winding up of the Company (other than pursuant to a transaction in which the assets of the
Company are distributed to an entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of shares of the Company); or 

(d) the sale, directly or indirectly, of all or substantially all of the Company’s and its Subsidiaries’ assets (determined on a
consolidated basis), other than to a Person described in clauses (i), (ii) or (iii) of Section 2.5(a) above. 
 Notwithstanding the
foregoing, (i) a restructuring, reorganization or similar or analogous event in which the stockholders of the Company immediately before such event have “Beneficial Ownership” (within the meaning of
Rule 13d-3 under the Exchange Act) of the Company, or of the resulting entity, immediately after such event in substantially the same proportions as their ownership of Shares of the Company immediately
before such event shall not constitute a Change in Control and (ii) an IPO shall not be considered a Change in Control. 

  
 2 

 2.6. “Code” means the Internal Revenue Code of 1986, as amended. 

2.7. “Company” means BioAtla, Inc., a Delaware corporation, or any successor corporation or company. 

2.8. “Committee” means the Compensation Committee of the Board, provided that the Committee shall at all times have at least
two members, each of whom shall be a “non-employee director” as defined in Rule 16b-3 under the Exchange Act and the regulations issued thereunder and an
“independent director” under the rules of any applicable stock exchange. 
 2.9. “Consultant” means a natural
person (within the meaning of Form S-8 of the Securities Act) who provides bona fide services to the Company or any Subsidiary other than in connection with the offer or sale of Shares or other securities
or shares in a capital-raising transaction and is not engaged in activities that directly or indirectly promote or maintain a market for the Shares or other securities of the Company. 

2.10. “Disability” means, 

(a) if the applicable Participant is party to an effective employment, consulting, severance or similar agreement with the Company or a
Subsidiary, and such term is defined therein, “Disability” shall have the meaning provided in such agreement; 
 (b) if the
applicable Participant is not a party to an effective employment, consulting, severance or similar agreement with the Company or a Subsidiary or if no definition of “Disability” is set forth in the applicable employment, consulting,
severance or similar agreement, “Disability” shall have the meaning provided in the applicable Award Agreement; 
 (c) if neither
clause (a) nor clause (b) applies, then “Disability” shall mean that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be
expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months. 
 2.11.
“Effective Date” means the date that the Plan is approved by the stockholders of the Company. 
 2.12.
“Employee” means an officer or other employee of the Company or a Subsidiary, including without limitation a director who is such an employee. 

2.13. “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

2.14. “Fair Market Value” means, on any given date (i) if the Shares are listed on any established stock exchange or a
national market system, including without limitation The NASDAQ Global Market, the closing sales price for such Shares as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other
source as the Committee deems reliable (or, if no closing sales price was reported on that date, on the last trading date such closing sales price was reported); (ii) if clause (i) does not apply, then if the Shares are regularly quoted by
a recognized securities dealer but selling prices are not reported, the mean between the high bid and low asked prices for the Shares on the day of determination 

  
 3 

 
(or, if no bids and asks were reported on that date, on the last trading date such bids and asks were reported); or (iii) if neither clause (i) nor clause (ii) applies, such value
as the Committee in its discretion may in good faith determine in accordance with Section 409A of the Code and the regulations thereunder (and, with respect to Incentive Stock Options, in accordance with Section 422 of the Code and the
regulations thereunder). 
 2.15. “IPO” means the initial public offering of the Company’s securities, other than
pursuant to a Form S-8 (or any successor form thereto). 
 2.16. “Incentive Stock
Option” means an Option or portion thereof intended to meet the requirements of an incentive stock option as defined in Section 422 of the Code and designated as an Incentive Stock Option, and which in fact meets such requirements of
Section 422 of the Code. 
 2.17. “Incumbent Director” means a director who either (1) is a member of the Board
as of the Effective Date or (2) is elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination. 

2.18. “Non-Employee Director” means a member of the Board who is not an Employee.

 2.19. “Non-Qualified Option” means an Option or portion thereof that is
designated as not being an Incentive Stock Option or that does not otherwise qualify as an Incentive Stock Option. 
 2.20.
“Option” means a right granted under Section 6.1 of the Plan to purchase a specified number of Shares at a specified price. An Option may be an Incentive Stock Option or a Non-Qualified
Option; provided, however, that unless otherwise explicitly stated in an Award Agreement, each Option is hereby designated as a Non-Qualified Option. 

2.21. “Other Stock-Based Award” means a right granted under Section 6.7 of the Plan. 

2.22. “Participant” means any Employee, Non-Employee Director or Consultant who
receives an Award. 
 2.23. “Performance Goals” means any goals established by the Committee in its sole discretion, the
attainment of which is substantially uncertain at the time such goals are established. Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the individual Participant or a
Subsidiary, division, department or function within the Company or a Subsidiary. Performance Goals may be measured on an absolute or relative basis. Relative performance may be measured, for example, by a group of peer companies or by a financial
market index. Performance Goals may include, but are not limited to: achievement of specified research and development, publication, clinical and/or regulatory milestones, total shareholder return, earnings before interest, taxes, depreciation and
amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of the Shares, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or
strategic transactions, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense,
margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per Share, sales or 

  
 4 

 
market shares and number of customers, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group, and any
combination of any of the foregoing criteria. If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company or a Subsidiary, or the manner in which it conducts its business, or other
events or circumstances render the Performance Goals unsuitable, the Committee may modify such Performance Goals and/or the related minimum, target, maximum and/or other acceptable levels of achievement, in whole or in part, as the Committee deems
appropriate and equitable. 
 2.24. “Performance Period” means the period selected by the Committee during which
performance is measured for the purpose of determining the extent to which a Performance Goal has been achieved. 
 2.25.
“Performance Stock” means Shares awarded by the Committee under Section 6.6 of the Plan that are subject to Performance Goals. 

2.26. “Performance Stock Unit” means the right granted under Section 6.5 of the Plan to receive, on the date of
settlement, one Share or an amount equal to the Fair Market Value of one Share, which right is subject to Performance Goals. Performance Stock Units may be settled in cash, Shares or any combination thereof; provided, however, that unless otherwise
provided in an Award Agreement, Performance Stock Units shall be settled in Shares. 
 2.27. “Person” means an individual,
corporation, partnership, association, limited liability company, estate or other entity. 
 2.28. “Restricted Stock” means
a Share awarded by the Committee under Section 6.3 of the Plan. 
 2.29. “Restricted Stock Unit” means the right
granted under Section 6.4 of the Plan to receive, on the date of settlement, one Share or an amount equal to the Fair Market Value of one Share. An Award of Restricted Stock Units may be settled in cash, Shares or any combination of the
foregoing; provided, however, that unless otherwise provided in an Award Agreement, Restricted Stock Units shall be settled in Shares. 

2.30. “Restriction Period” means the period during which Performance Stock, Performance Stock Units, Restricted Stock and
Restricted Stock Units are subject to forfeiture. 
 2.31. “SAR” means a stock appreciation right awarded by the Committee
under Section 6.2 of the Plan. 
 2.32. “Securities Act” means the Securities Act of 1933, as amended. 

2.33. “Share” means one share of the Company’s common stock, par value $0.0001 per share. 

2.34. “Subsidiary” means any corporation, partnership, joint venture, company or other business entity of which 50% or more
of the outstanding voting power is beneficially owned, directly or indirectly, by the Company. 

  
 5 

 2.35. “Ten Percent Stockholder” means a Person who on any given date owns,
either directly or indirectly (taking into account the attribution rules contained in Section 424(d) of the Code), shares possessing more than 10% of the total combined voting power of all classes of shares of the Company, a “parent”
or a “subsidiary” (as the terms “parent” and “subsidiary” are defined in Code Section 424). 
 Section 3.
Eligibility. 
 Any Employee, Non-Employee Director or Consultant shall be eligible to be
selected to receive an Award under the Plan, as determined in the sole discretion of the Committee; provided, however, that only persons who are Employees may be granted Incentive Stock Options. 

Section 4. Administration of the Plan. 

4.1. The Plan and all Award Agreements shall be administered by the Committee. Any action of the Committee in administering the Plan and an
Award Agreement shall be final, conclusive and binding on all Persons, including without limitation the Company, its Subsidiaries, Participants, Persons claiming rights from or through Participants and stockholders of the Company. No member of the
Committee (or any person to whom the Committee has delegated authority to act under the Plan) shall be personally liable for any action, determination, or interpretation taken or made in good faith by the Committee (or such person) with respect to
the Plan or any Awards granted hereunder, and all members of the Committee (and such persons to whom the Committee has delegated authority to act under the Plan) shall be fully indemnified and protected by the Company in respect of any such action,
determination or interpretation to the fullest extent permitted by law. 
 4.2. Subject to the provisions of the Plan, the Committee shall
have full and final authority in its discretion to (i) select the Employees, Non-Employee Directors and Consultants who will receive Awards pursuant to the Plan; provided that Awards granted to Non-Employee Directors shall be subject to ratification by the full Board; (ii) determine the type or types of Awards to be granted to each Participant; (iii) determine the number of Shares to which an
Award will relate, the terms and conditions of any Award granted under the Plan (including, but not limited to, restrictions as to vesting, Performance Goals relating to an Award, transferability or forfeiture, exercisability or settlement of an
Award, waivers or accelerations thereof, and waivers of or modifications to Performance Goals relating to an Award, based in each case on such considerations as the Committee shall determine) and all other matters to be determined in connection with
an Award; (iv) determine the exercise price or purchase price (if any) of an Award; (v) determine whether, to what extent, and under what circumstances an Award may be cancelled, forfeited, or surrendered; (vi) determine whether (and,
if necessary, certify that) Performance Goals to which an Award is subject are satisfied; (vii) determine whether Participants will be permitted to defer the settlement of certain Awards; (viii) correct any defect or supply any omission or
reconcile any inconsistency in the Plan and Award Agreements, and adopt, amend and rescind such rules, regulations, guidelines, forms of agreements and instruments relating to the Plan and Award Agreements as it may deem necessary or advisable;
(ix) construe and interpret the Plan and Award Agreements; and (x) make all other determinations as it may deem necessary or advisable for the administration of the Plan and Award Agreements. Notwithstanding anything in the Plan or an
Award Agreement to the contrary, no Award may be repriced, replaced or regranted through cancellation, nor may any underwater Option or underwater SAR be repurchased for cash, in any case, without the approval of the stockholders of the Company,
provided that nothing herein shall prevent the Committee from taking any action provided for in Sections 7 or 8. 

  
 6 

 4.3. To the extent permitted by applicable law and the Company’s by-laws, the Committee may delegate some or all of its authority with respect to the Plan and Awards to any executive officer of the Company or any other person or persons designated by the Committee, in each case,
acting individually or as a committee, provided that the Committee may not delegate its authority hereunder to any person to make Awards to (a) Employees who are (i) subject to the requirements of
Rule 16b-3 of the Exchange Act or (ii) officers or other Employees who are delegated authority by the Committee pursuant to this Section 4.3 or (b) members of the Board. Any delegation
hereunder shall be subject to the restrictions and limits that the Committee specifies at the time of such delegation or thereafter in its sole discretion. The Committee may at any time rescind the authority delegated to any person pursuant to this
Section 4.3. Any action undertaken by any such person or persons in accordance with the Committee’s delegation of authority pursuant to this Section 4.3 shall have the same force and effect as if undertaken directly by the Committee.

 4.4. Notwithstanding any other provision to the contrary, (i) Awards granted to Non-Employee
Directors shall be administered by the full Board, and any authority reserved under the Plan for the Committee with regard to Awards granted to Non-Employee Directors shall be exercised by the full Board and
(ii) prior to the occurrence of the IPO, the Plan, all Awards and all Award Agreements shall be administered by the Board (unless such authority is delegated by the Board to a committee thereof), and all references herein to
“Committee” shall be deemed to refer to the Board. 
 Section 5. Shares Subject to the Plan. 

5.1. Subject to adjustment as provided in Section 8 hereof and this Section 5, the maximum number of Shares that may be issued
pursuant to Awards under the Plan shall be 25,215,823 (the “Cap”). No more than 25,215,823 Shares issued under the Plan may be issued pursuant to the exercise of Incentive Stock Options. The Shares issued under the Plan may, at the
election of the Board, be (i) authorized but previously unissued Shares or (ii) Shares previously issued and outstanding and reacquired by the Company. Notwithstanding the foregoing, Shares issued under Awards granted in assumption,
substitution or exchange for previously granted awards of a company acquired by the Company or any Subsidiary (“Substitute Awards”) shall not count against the Cap, and to the extent permitted by the rules of the stock exchange on
which the Shares are then listed or quoted, shares under a stockholder approved plan of an acquired company (adjusted to reflect the transaction) may be used for Awards under the Plan and do not count against the Cap. In addition, Shares issued
pursuant to Awards granted under the Plan that satisfy the requirements of the “inducement grant exception” under NASDAQ Listing Rule 5635(c) (or any successor rule or analogous rule of another applicable stock exchange)
(“Inducement Awards”) shall not count against the Cap. The Award Agreement for any Award intended to be an Inducement Award must state that the Award subject thereto is intended to be an Inducement Award. 

  
 7 

 5.2. If any Shares subject to an Award under the Plan are forfeited or such Award otherwise
terminates for any reason whatsoever without an actual distribution of Shares to the Participant, any Shares counted against the number of Shares available for issuance pursuant to the Plan with respect to such Award shall, to the extent of any such
forfeiture or termination, be added back to the Cap and shall again be available for Awards under the Plan; provided, however, that (i) such treatment shall not apply for Substitute Awards or Inducement Awards and (ii) the Committee may
adopt procedures for the counting of Shares relating to any Award to ensure appropriate counting, avoid double counting, provide for adjustments in any case in which the number of Shares actually distributed differs from the number of Shares
previously counted in connection with such Award, and if necessary, to comply with applicable law or regulations. In addition, and notwithstanding anything contained herein to the contrary, Shares tendered in payment of the exercise price or
withholding taxes with respect to an Award shall not become, or again be, available for Awards under the Plan. 
 Section 6. Awards. 

Awards may be granted on the terms and conditions set forth in this Section 6. In addition, the Committee may impose on any Award or the
settlement or exercise thereof, at the grant date or thereafter, such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine, including without limitation terms requiring forfeiture of
Awards in the event of a Participant’s termination of employment or other service with the Company or any Subsidiary; provided, however, that the Committee shall retain full power to accelerate or waive any such additional term or condition as
it may have previously imposed (provided that, in any case, any such action is permitted under Code Section 409A). The right of a Participant to exercise or receive a grant or settlement of any Award, and the timing thereof, may be subject to
such Performance Goals as may be determined by the Committee. Each Award, and the terms and conditions applicable thereto, shall be evidenced by an Award Agreement. 

6.1. Options. Options give a Participant the right to purchase a specified number of Shares from the Company for a specified time
period at a fixed exercise price, as provided in the applicable Award Agreement. Options may be either Incentive Stock Options or Non-Qualified Options; provided that Incentive Stock Options may be granted
only to employees of the Company or a “subsidiary” (as defined in Code Section 424(f)) of the Company. The grant of Options shall be subject to the following terms and conditions: 

(a) Exercise Price. The price per Share at which Shares may be purchased upon exercise of an Option shall be determined by the Committee
and specified in the Award Agreement, but shall be not less than the Fair Market Value of one Share on the grant date (or 110% of the Fair Market Value of one Share on the grant date in the case of an Incentive Stock Option granted to a Ten Percent
Stockholder). 
 (b) Term of Options. The term of an Option shall be specified in the Award Agreement, but shall in no event be
greater than ten years from the grant date (or five years from the grant date in the case of an Incentive Stock Option granted to a Ten Percent Stockholder). 

  
 8 

 (c) Exercise of Option. Each Award Agreement with respect to an Option shall specify
the time or times at which an Option may be exercised in whole or in part and the terms and conditions applicable thereto, including without limitation (i) a vesting schedule which may be based upon the passage of time, attainment of
Performance Goals or a combination thereof, (ii) whether the exercise price for an Option shall be paid in cash, with Shares, with any combination of cash and Shares, or with other legal consideration that the Committee may deem appropriate and
to the extent permitted by applicable law, (iii) the methods of payment, which may include payment through cashless and net exercise arrangements, to the extent permitted by applicable law and (iv) the methods by which, or the time or
times at which, Shares will be delivered or deemed to be delivered to Participants upon the exercise of such Option. Payment of the exercise price shall in all events be made within three days after the date of exercise of an Option. With respect to
any Participant who is subject to Section 16 of the Exchange Act with respect to the Company, such Participant may direct the Company to reduce the number of Shares that would otherwise be deliverable upon the exercise of his or her Option by
the number of Shares having a Fair Market Value on the date of exercise equal to the exercise price of the portion of the Option then being exercised. 

(d) Incentive Stock Options. Each Participant awarded an Incentive Stock Option under the Plan shall notify the Company in writing
immediately after the date he or she makes a “disqualifying disposition” (as defined in Section 421(b) of the Code) of any Shares acquired pursuant to the exercise of such Incentive Stock Option. The Company may, if determined by the
Committee and in accordance with procedures established by it, retain possession of any Shares acquired pursuant to the exercise of an Incentive Stock Option as agent for the applicable Participant until the end of any period during which a
disqualifying disposition could occur, subject to complying with any instructions from such Participant as to the sale of such Shares. The aggregate Fair Market Value, determined as of the grant date, for Awards granted under the Plan (or any other
stock or share option plan required to be taken into account under Section 422(d) of the Code) that are intended to be Incentive Stock Options which are first exercisable by the Participant during any calendar year shall not exceed $100,000. To
the extent an Award purporting to be an Incentive Stock Option exceeds the limitation in the previous sentence or does not otherwise qualify as an Incentive Stock Option, the portion of the Award in excess of such limit or that does not so qualify
shall be a Non-Qualified Option. 
 (e) No Dividend Equivalent Rights. No Participant shall
be entitled to dividend equivalent rights or payments with respect to any Shares underlying the Participant’s Options. 
 6.2. Stock
Appreciation Rights. A SAR shall confer on the Participant a right to receive, upon exercise thereof, the excess of (i) the Fair Market Value of one Share on the date of exercise over (ii) the grant price of the SAR as determined by
the Committee, but which may never be less than the Fair Market Value of one Share on the grant date. No payment from the Participant shall be required to exercise a SAR. The grant of SARs shall be subject to the following terms and conditions: 

(a) General. Each Award Agreement with respect to a SAR shall specify the number of SARs granted, the grant price of the SAR, the time
or times at which the SAR may be exercised in whole or in part (including without limitation vesting upon the passage of time, the attainment of Performance Goals or a combination thereof), the method of exercise, method of settlement (in cash,
Shares or a combination thereof), method by which Shares will be delivered or deemed to be delivered to Participants (if applicable) and any other terms and conditions of the SAR. Unless provided otherwise in an Award Agreement, all SARs shall be
settled in Shares. 

  
 9 

 (b) Term. The term of a SAR shall be specified in the Award Agreement, but shall in
no event be greater than ten years from the grant date. 
 (c) No Dividend Equivalent Rights. No Participant shall be entitled to
dividend equivalent rights or payments with respect to any Shares underlying the Participant’s SARs. 
 6.3. Restricted Stock.
An Award of Restricted Stock is a grant by the Company of a specified number of Shares to the Participant, which Shares are subject to forfeiture upon the occurrence of specified events during the Restriction Period. Such an Award shall be subject
to the following terms and conditions: 
 (a) General. Each Award Agreement with respect to Restricted Stock shall specify the
duration of the Restriction Period and/or each installment thereof, the conditions under which the Restricted Stock may be forfeited to the Company, and the amount, if any, the Participant must pay to receive the Restricted Stock. Such restrictions
may include a vesting schedule based upon the passage of time. 
 (b) Transferability. During the Restriction Period, the
transferability of Restricted Stock shall be prohibited or restricted in the manner and to the extent prescribed in the applicable Award Agreement. Such restrictions may include, without limitation, rights of repurchase or first refusal in the
Company or provisions subjecting the Restricted Stock to a continuing substantial risk of forfeiture in the hands of any transferee. 
 (c)
Stockholder Rights. Unless otherwise provided in the applicable Award Agreement, during the Restriction Period the Participant shall have all the rights of a stockholder with respect to Restricted Stock, including, without limitation, the
right to receive dividends thereon (whether in cash or Shares) and to vote such Shares of Restricted Stock in accordance with the Company’s by-laws. Dividends may, in the discretion of the Committee, be
paid currently or subject to the same restrictions as the underlying Restricted Stock, in either case, as set forth in the applicable Award Agreement (and the Committee may, in its sole discretion, withhold any cash dividends paid on Restricted
Stock until the restrictions applicable to such Restricted Stock have lapsed); provided, however, that dividends paid on unvested Restricted Stock that is subject to Performance Goals shall not be paid or released unless and until the applicable
Performance Goals have been achieved. 
 (d) Additional Matters. Upon the Award of Restricted Stock, the Committee may direct the
number of Shares subject to such Award be issued to the Participant or placed in a restricted stock account (including without limitation an electronic account) with the transfer agent and in either case designating the Participant as the registered
owner. The certificate(s), if any, representing such Shares shall be physically or electronically legended, as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period and, if issued to the
Participant, returned to the Company to be held in escrow during the Restriction Period. In all cases, the Participant shall sign a stock power or share transfer form (as appropriate) endorsed in blank to the Company to be held in escrow during the
Restriction Period. 

  
 10 

 6.4. Restricted Stock Units. Restricted Stock Units are solely a device for the
measurement and determination of the amounts to be paid to a Participant under the Plan. Restricted Stock Units do not constitute Shares and shall not be treated as (or as giving rise to) property or as a trust fund of any kind; provided, however,
that the Company may establish a bookkeeping reserve to meet its obligations hereunder or a trust or other funding vehicle that would not cause the Plan to be deemed to be funded for tax purposes or for purposes of Title I of the Employee Retirement
Income Security Act of 1974, as amended. The right of any Participant in respect of an Award of Restricted Stock Units shall be no greater than the right of any unsecured general creditor of the Company. The grant of Restricted Stock Units shall be
subject to the following terms and conditions: 
 (a) Restriction Period. Each Award Agreement with respect to Restricted Stock Units
shall specify the duration of the Restriction Period, if any, and/or each installment thereof and the conditions under which such Award may be forfeited to the Company. Such restrictions may include a vesting schedule based upon the passage of time.

 (b) Settlement. Unless otherwise provided in an Award Agreement (i) an Award of Restricted Stock Units shall be settled in
Shares, provided that any fractional Restricted Stock Units shall be settled in cash and (ii) subject to the Participant’s continued employment or other service with the Company or a Subsidiary from the date of grant through the expiration
of the Restriction Period (or applicable portion thereof), the vested portion of an Award of Restricted Stock Units shall be settled within 60 days after the expiration of the Restriction Period (or applicable portion thereof). 

(c) Stockholder Rights. Nothing contained in the Plan shall be construed to give any Participant rights as a stockholder with respect
to an Award of Restricted Stock Units (including, without limitation, any voting, dividend or derivative or other similar rights). Notwithstanding the foregoing, the Committee may provide in an Award Agreement that amounts equal to any dividends
declared during the Restriction Period or deferral period on the Shares represented by an Award of Restricted Stock Units will be credited to the Participant’s account and settled in Shares unless otherwise specified in the applicable Award
Agreement at the same time (and subject to the same forfeiture restrictions) as the Restricted Stock Units to which such dividend equivalents relate (with the number of Shares released in payment of such dividend equivalents to equal the amount of
dividend equivalents then being settled, divided by the Fair Market Value of one Share on the settlement date of such dividend equivalents); provided, however, that the Committee may determine at or after the grant date to settle any such dividend
equivalents in cash. 
 6.5. Performance Stock Units. Performance Stock Units are solely a device for the measurement and
determination of the amounts to be paid to a Participant under the Plan. Performance Stock Units do not constitute Shares and shall not be treated as (or as giving rise to) property or as a trust fund of any kind; provided, however, that the Company
may establish a bookkeeping reserve to meet its obligations hereunder or a trust or other funding vehicle that would not cause the Plan to be deemed to be funded for tax purposes or for purposes of Title I of the

  
 11 

 
Employee Retirement Income Security Act of 1974, as amended. The right of any Participant in respect of an Award of Performance Stock Units shall be no greater than the right of any unsecured
general creditor of the Company. The grant of Performance Stock Units shall be subject to the following terms and conditions: 
 (a)
Restriction Period. Each Award Agreement with respect to Performance Stock Units shall specify the duration of the Performance Period and the Restriction Period, if any, and/or each installment thereof, the Performance Goals applicable to the
Performance Stock Units and the conditions under which the Performance Stock Units may be forfeited to the Company. Such restrictions shall include a vesting schedule based on the attainment of one or more Performance Goals. 

(b) Settlement. Unless otherwise provided in an Award Agreement, subject to the Participant’s continued employment or other
service with the Company or a Subsidiary from the grant date through the expiration of the Restriction Period (or applicable portion thereof), the vested portion of an Award of Performance Stock Units shall be settled within 60 days after the
expiration of the Restriction Period (or applicable portion thereof). Unless provided otherwise in an Award Agreement, all Performance Stock Units will be settled in Shares (except that fractional Performance Stock Units shall be settled in cash).

 (c) Stockholder Rights. Nothing contained in the Plan shall be construed to give any Participant rights as a stockholder with
respect to an Award of Performance Stock Units (including, without limitation, any voting, dividend or derivative or other similar rights). Notwithstanding the foregoing, the Committee may provide in an Award Agreement that amounts equal to any
dividends declared by the Company during the Restriction Period on the Shares represented by an Award of Performance Stock Units will be credited to the Participant’s account and settled in cash or Shares at the same time (and subject to the
same forfeiture restrictions and Performance Goals) as the Performance Stock Units to which such dividend equivalents relate (with the number of Shares released in payment of such dividend equivalents to equal the amount of dividend equivalents then
being settled in Shares, divided by the Fair Market Value of one Share on the settlement date of such dividend equivalents). 
 6.6.
Performance Stock. An Award of Performance Stock is a grant by the Company of a specified number of Shares to the Participant, which Shares are conditional on the achievement of one or more Performance Goals during the Performance Period and
subject to forfeiture upon the occurrence of specified events during the Restriction Period. An Award of Performance Stock shall be subject to the following terms and conditions. 

(a) General. Each Award Agreement with respect to Performance Stock shall specify the duration of the Performance Period and the
Restriction Period, if any, and/or each installment thereof, the Performance Goals applicable to the Performance Stock and the conditions under which the Performance Stock may be forfeited to the Company, and the amount, if any, the Participant must
pay to receive the Performance Stock. 
 (b) Transferability. During the Restriction Period, if any, the transferability of
Performance Stock shall be prohibited or restricted in the manner and to the extent prescribed in the applicable Award Agreement. Such restrictions may include, without limitation, rights of repurchase or first refusal in the Company or provisions
subjecting the Performance Stock to a continuing substantial risk of forfeiture in the hands of any transferee. 

  
 12 

 (c) Stockholder Rights. Unless otherwise provided in the applicable Award Agreement,
during the Restriction Period the Participant shall have all the rights of a stockholder with respect to Performance Stock, including, without limitation, the right to receive dividends thereon (whether in cash or Shares), but only to the extent
that Performance Stock vests based on the achievement of Performance Goals, and to vote such shares of Performance Stock. Dividends shall be subject to the same restrictions (and Performance Goals) as the underlying Performance Stock and the
Committee shall withhold any cash dividends paid on Performance Stock until the Performance Goals are achieved and restrictions applicable to such Performance Stock have lapsed. 

6.7. Other Stock-Based Awards. The Committee is authorized, subject to limitations under applicable law, to grant to Participants any
type of Award (in addition to those Awards provided in Sections 6.1, 6.2, 6.3, 6.4, 6.5 and 6.6 hereof) that is payable in, or valued in whole or in part by reference to, Shares, and that is deemed by the Committee to be consistent with the
purposes of the Plan, including, without limitation, fully vested Shares and dividend equivalents (“Other Awards”). 
 6.8.
Termination of Employment or Other Service. Unless otherwise provided in an Award Agreement, and except as otherwise provided in Section 7.2 hereof, upon a Participant’s termination of employment or other service with the Company
and its Subsidiaries (x) for any reason other than for Cause, the unvested portion of each Award shall be immediately forfeited upon such termination with no compensation or other payment due the Participant, and the vested portion of each
Option and SAR shall be exercisable for the period set forth in the Award Agreement (but not beyond the stated term of such vested Option or vested SAR) or (y) for Cause, all vested and unvested Awards granted to such Participant shall be
immediately forfeited upon such termination with no compensation or other payment due the Participant. 
 Section 7. Change in Control. 

7.1. General. Unless otherwise provided in an Award Agreement, a Change in Control shall not, in and of itself, accelerate the vesting,
settlement or exercisability of outstanding Awards. Notwithstanding the foregoing and unless otherwise provided in an Award Agreement, if (i) the successor corporation or company (or its direct or indirect parent) does not agree to assume an
outstanding Award or does not agree to substitute or replace such Award with an award involving the ordinary equity securities of such successor corporation (or its direct or indirect parent) on terms and conditions necessary to preserve the rights
of the applicable Participant with respect to such Award, (ii) the securities of the Company or the successor corporation or company (or its direct or indirect parent) will not be publicly traded on a U.S. securities exchange immediately
following such Change in Control or (iii) the Change in Control is not approved by a majority of the Incumbent Directors immediately prior to such Change in Control, then the Committee, in its sole discretion, may take one or more of the
following actions with respect to all, some or any such Awards: (a) accelerate the vesting and, if applicable, exercisability of such Awards such that the Awards are fully vested and, if applicable, exercisable (effective immediately prior to
such Change in Control); (b) with respect to any Awards that do not constitute “non-

  
 13 

 
qualified deferred compensation” within the meaning of Code Section 409A, accelerate the settlement of such Awards upon such Change in Control; (c) with respect to Awards that
constitute “non-qualified deferred compensation” within the meaning of Code Section 409A, terminate all such Awards and settle all such Awards for a cash payment equal to the Fair Market Value
of the Shares underlying such Awards less the amount the Participant is required to pay for such Shares, if any, provided that (I) such Change in Control satisfies the requirements of Treasury Regulation
Section 1.409A-3(i)(5)(v), (vi) or (vii) and (II) all other arrangements that would be aggregated with such Awards under Code Section 409A are terminated and liquidated within
30 days before or 12 months after such Change in Control; (d) cancel outstanding Options and SARs in exchange for a cash payment in an amount equal to the excess, if any, of the Fair Market Value of the Shares underlying the
unexercised portion of the Option or SAR as of the date of the Change in Control over the exercise price or grant price, as the case may be, of such portion, provided that any Option or SAR with a per Share exercise price or grant price, as the case
may be, that equals or exceeds the Fair Market Value of one Share on the date of the Change in Control shall be cancelled with no payment due the Participant and (e) take such other actions as the Committee deems appropriate (to the extent
permitted by Code Section 409A). If any action is taken with respect to any Award under items (a) through (e) of this Section 7.1 and such Award is subject to Performance Goals, such Performance Goals shall be deemed satisfied
based on the actual level of achievement of the applicable Performance Goals through the date of the Change in Control or, if determined by the Committee in its sole discretion prior to such Change in Control, using the applicable target level of
achievement rather than such actual level of achievement. The judgment of the Committee with respect to any matter referred to in this Section 7.1 shall be conclusive and binding upon each Participant (and all other Persons) without the need
for any amendment to the Plan or any Award or Award Agreement. Notwithstanding the foregoing, no Award that constitutes “non-qualified deferred compensation” (within the meaning of Section 409A
of the Code) shall be payable upon the occurrence of a Change in Control unless such Change in Control satisfies the requirements of Treasury Regulation Section 1.409A-3(i)(5). 

7.2. Termination Following a Change in Control. Notwithstanding anything contained in the Plan to the contrary, unless otherwise
provided in an Award Agreement, in the event that Awards under the Plan are assumed in connection with a Change in Control or are substituted with new awards, in either case, pursuant to Section 7.1 above, and a Participant’s employment or
other service with the Company and its Subsidiaries is terminated by the Company or a Subsidiary without Cause or due to Disability or as the result of the Participant’s death, in any case, within 24 months following a Change in Control,
(i) the unvested portion of such Participant’s Awards (including without limitation any awards received in substitution of an Award) shall vest in full (with any applicable Performance Goals being deemed to have been achieved at target or,
if greater, actual levels of performance), (ii) Awards of Options and SARs (including without limitation options and stock or share appreciation rights received in substitution of an Award) shall remain exercisable by the Participant or the
Participant’s beneficiary or legal representative, as the case may be, for a period of one-year thereafter (but not beyond the stated term of such Option or SAR), (iii) all Restricted Stock Units and
Performance Stock Units (including without limitation restricted stock units and performance stock units received in substitution of an Award) shall be settled within 30 days after such termination and (iv) all Other Stock-Based Awards
(including without limitation any received in substitution of an Award) shall be settled within 30 days after such termination; provided, however, that with respect to clauses (iii) and (iv), if settlement of such Awards on the date
described in this Section 7.2 would violate Code Section 409A, then such Award instead shall be settled in full at the time it otherwise would have been settled in connection with a termination of employment or service without Cause or due
to death or Disability, as applicable. 

  
 14 

 Section 8. Adjustments upon Changes in Capitalization. 

8.1. In order to prevent dilution or enlargement of the rights of Participants under the Plan as a result of any share dividend,
recapitalization, forward share split or reverse share split, reorganization, merger, consolidation, amalgamation, spin-off, combination, extraordinary cash distribution or other similar or analogous corporate
transaction or event that affects the Shares, the Committee shall adjust (i) the number and kind of Shares which may thereafter be issued in connection with Awards, (ii) the number and kind of Shares issuable in respect of outstanding
Awards, (iii) the Cap and the specific limitations under Section 5 hereof and (iv) the exercise or grant price relating to any Award. Any such adjustment shall be made in an equitable manner which reflects the effect of such
transaction or event. It is provided, however, that in the case of any such transaction or event, the Committee may make any additional adjustments to the items in clauses (i) through (iv) above which it deems appropriate in the
circumstances, or make provision for a cash payment with respect to any outstanding Award. 
 8.2. In addition to the adjustments described
in Section 8.1 above, the Committee is authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards, including without limitation any Performance Goals, in recognition of unusual or nonrecurring events
affecting the Company or any Subsidiary, or in response to changes in applicable laws, regulations, or accounting principles (including, without limitation, (a) asset write-downs; (b) significant litigation or claim judgments or
settlements; (c) the effect of changes in tax laws, accounting standards or principles, or other laws or regulatory rules affecting reporting results; (d) any reorganization and/or restructuring programs or change in the corporate
structure or capital structure of the Company or a Subsidiary; (e) extraordinary nonrecurring items as described in management’s discussion and analysis of financial condition and results of operations appearing in the Company’s
annual report to stockholders for the applicable year or period; (f) acquisitions or divestitures; (g) any other specific unusual or nonrecurring events or objectively determinable category thereof; (h) foreign exchange gains and
losses; and (i) a change in the Company’s fiscal year). 
 8.3. If Sections 7 and 8 hereof could both apply to an event,
Section 7 hereof shall control. 
 Section 9. Termination and Amendment. 

9.1. Changes to the Plan and Awards. The Board may amend, alter, suspend, discontinue, or terminate the Plan without the consent of the
Company’s stockholders or Participants, except that any such amendment or alteration shall be subject to the approval of the Company’s stockholders if (i) such action would increase the number of Shares subject to the Plan (other than
in connection with adjustments under Section 8.1 hereof), (ii) such action would decrease the price at which Awards may be granted, or (iii) such stockholder approval is required by any applicable federal, state or foreign law or
regulation or the rules of any stock exchange or automated quotation system on which the Shares may then be listed or quoted, and the Board may 

  
 15 

 
otherwise, in its discretion, determine to submit such other changes to the Plan to the Company’s stockholders for approval; provided, however, that except as provided in Section 18
hereof, without the consent of an affected Participant, no amendment, alteration, suspension, discontinuation, or termination of the Plan may materially and adversely affect the rights of such Participant under any outstanding Award unless such
amendment, alteration, suspension, discontinuation or termination is required by law or the rules of any applicable securities exchange. 

9.2. The Committee may waive any conditions or rights under, or amend, alter, suspend, discontinue, or terminate, any Award theretofore
granted and any Award Agreement relating thereto; provided, however, that except as provided in Section 18 hereof, without the consent of an affected Participant, no such amendment, alteration, suspension, discontinuation, or termination of any
Award may materially and adversely affect the rights of such Participant under such Award unless such amendment, alteration, suspension, discontinuation or termination is required by law or the rules of any applicable securities exchange. 

9.3. Notwithstanding anything in Section 8 hereof or this Section 9 to the contrary, any Performance Goal applicable to an Award
shall not be deemed a fixed contractual term, but shall remain subject to adjustment by the Committee, in its discretion at any time in view of the Committee’s assessment of the Company’s strategy, performance of comparable companies, and
other circumstances. 
 9.4. No Repricing. Notwithstanding anything in the Plan or an Award Agreement to the contrary, no Award may
be repriced, replaced or regranted through cancellation, nor may any underwater option or underwater SAR be repurchased for cash, in any case, without the approval of the stockholders of the Company, provided that nothing herein shall prevent the
Committee from taking any action provided for in Sections 7 and/or 8 hereof. 
 Section 10. No Right to Award, Employment or Service. 

No Employee, Consultant or Non-Employee Director shall have any claim to be granted any Award under the
Plan, and there is no obligation that the terms of Awards be uniform or consistent among Participants. Neither the Plan nor any action taken hereunder shall be construed as giving any Participant any right to be retained in the employ or service of
the Company or any Subsidiary. For purposes of the Plan, a transfer of employment or service between the Company and any of its Subsidiaries shall not be deemed a termination of employment or service; provided, however, that individuals employed by,
or otherwise providing services to, an entity that ceases to be a Subsidiary shall be deemed to have incurred a termination of employment or service, as the case may be, as of the date such entity ceases to be a Subsidiary unless such individual
becomes an employee of, or service provider to, the Company or another Subsidiary as of the date of such cessation. A change in status from Employee to Consultant shall be deemed to be a termination of employment, unless otherwise determined by the
Committee. The Committee may adopt rules and make determinations on how a leave of absence will impact an Award, including, without limitation, tolling the vesting schedule or treating such leave of absence as a termination of employment or other
service (such rules may be applied retroactively). 

  
 16 

 Section 11. Taxes. 

Each Participant must make appropriate arrangement for the payment of any taxes relating to an Award granted hereunder. The Company or any
Subsidiary is authorized to withhold from any payment relating to an Award under the Plan, including without limitation from a distribution of Shares or cash, amounts of withholding and other taxes due in connection with any transaction involving an
Award, and to take such other action as the Committee may deem advisable to enable the Company and Participants to satisfy obligations for the payment of withholding taxes and other tax obligations relating to any Award (including without limitation
withholding from any payroll or other payment due to a Participant). This authority shall include the ability to withhold or receive Shares or other property and to make cash payments in respect thereof in satisfaction of a Participant’s tax
obligations. With respect to any Participant who is subject to Section 16 of the Exchange Act with respect to the Company, such Participant may direct the Company to reduce the number of Shares that would otherwise be deliverable upon the
exercise, settlement or vesting of his or her Awards having a Fair Market Value on the date of exercise, settlement or vesting (as the case may be) equal to the withholding due in connection with such exercise, settlement or vesting (as the case may
be). Withholding of taxes in the form of Shares with respect to an Award shall not occur at a rate that equals or exceeds the rate that would result in liability accounting treatment. 

Section 12. Limits on Transferability; Beneficiaries. 

No Award or other right or interest of a Participant under the Plan shall be (i) pledged, encumbered, or hypothecated to, or in favor of,
or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company or any Subsidiary, or (ii) assigned or transferred by such Participant other than by will or the laws of descent and distribution, and
such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or (with respect to Awards other than Incentive Stock Options) his or her guardian or legal representative. Notwithstanding the foregoing, the
Committee may, in its discretion, provide that Non-Qualified Options, SARs, Performance Stock and Restricted Stock be transferable, without consideration, to immediate family members (i.e., children,
grandchildren or spouse), to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners (any vesting conditions shall be unaffected by such transfer). The Committee may attach to
such transferability feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a Person or a trust) to exercise the rights of the
Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other Person claiming any rights under the Plan from or through any Participant shall be
subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee. 

Section 13. Foreign Nationals. 

Without amending the Plan, Awards may be granted to Employees, Consultants and Non-Employee Directors
who are foreign nationals or are employed or providing services outside the United States or both, on such terms and conditions different from those specified in the Plan as may, in the judgment of the Committee, be necessary or desirable to further
the purpose of the Plan. Moreover, the Committee may approve such supplements to, or sub-plans, amendments, 

  
 17 

 
restatements or alternative versions of, the Plan as it may consider necessary or appropriate for such purposes without thereby affecting the terms of the Plan as in effect for any other purpose,
provided that no such supplements, sub-plans, amendments, restatements or alternative versions shall include any provisions that are prohibited by the terms of the Plan, as then in effect, unless the Plan
could have been amended to eliminate such prohibition without further approval by the stockholders of the Company. 
 Section 14. Securities Law
Requirements. 
 14.1. No Shares may be issued hereunder if the Company shall at any time determine that to do so would (i) violate
the listing requirements of an applicable securities or stock exchange, or adversely affect the registration or qualification of the Company’s Shares under any state or federal law, or otherwise violate any law, rule or regulation, or
(ii) require the consent or approval of any regulatory or supervising body or stockholders. In any of the events referred to in clause (i) or clause (ii) above, the issuance of such Shares shall be suspended and shall not be effective
unless and until it is done in compliance with all applicable laws, rules and regulations, and such listing, registration, qualifications, consents or approval shall have been effected or obtained free of any conditions not acceptable to the Company
in its sole discretion, notwithstanding any termination of any Award or any portion of any Award during the period when issuance has been suspended (provided, however, that if permitted under Code Section 409A, the Committee may toll the
expiration date of an Award such that it will not terminate during any such period of suspension). 
 14.2. The Committee may require, as a
condition to the issuance of Shares hereunder, representations, warranties and agreements to the effect that such Shares are being purchased or acquired by the Participant for investment only and without any present intention to sell or otherwise
distribute such Shares, and that the Participant will not dispose of such Shares in transactions which, in the opinion of counsel to the Company, would violate the registration provisions of the Securities Act and the rules and regulations
thereunder. 
 Section 15. Termination. 

Unless earlier terminated, the Plan shall terminate with respect to the grant of new Awards on the earlier of the 10-year anniversary of the Effective Date or the 10-year anniversary of the date the Plan was approved by the Board, and no Awards under the Plan shall thereafter be granted;
provided that no such termination shall impact Awards that were granted prior to such termination. 
 Section 16. Fractional Shares. 

The Company will not be required to issue any fractional Shares pursuant to the Plan. The Committee may provide for the elimination of
fractions and settlement of such fractional Shares in cash, in its sole discretion. 
 Section 17. Discretion. 

In exercising, or declining to exercise, any grant of authority or discretion hereunder, the Committee may consider or ignore such factors or
circumstances and may accord such weight to such factors and circumstances as the Committee alone and in its sole judgment deems appropriate and without regard to the effect such exercise, or declining to exercise such grant of authority or
discretion, would have upon the affected Participant, any other Participant, any Employee, any Consultant, any Non-Employee Director, the Company, any Subsidiary, any affiliate, any stockholder or any other
Person. 

  
 18 

 Section 18. Code Section 409A. 

The Plan and all Awards are intended to comply with, or be exempt from, Code Section 409A and all regulations, guidance, compliance
programs and other interpretative authority thereunder, and shall be interpreted in a manner consistent therewith without increasing the cost to the Company. In the event that a Participant is a “specified employee” within the meaning of
Code Section 409A, and a payment or benefit provided for under the Plan would be subject to additional tax under Code Section 409A if such payment or benefit is paid within six (6) months after such Participant’s “separation
from service” (within the meaning of Code Section 409A), then such payment or benefit shall not be paid (or commence) during the six (6) month period immediately following such Participant’s separation from service except as
provided in the immediately following sentence. In such an event, any payments or benefits that would otherwise have been made or provided during such six (6) month period and which would have incurred such additional tax under Code
Section 409A shall instead be paid to the Participant in a lump-sum, without interest, on the earlier of (i) the first business day of the seventh month following the month in which such
Participant’s separation from service occurs or (ii) the tenth business day following such Participant’s death (but not earlier than if such delay had not applied). A Participant’s right to receive any installment payments under
an Award Agreement, including without limitation as the result of any deferral of an Award in accordance with Code Section 409A, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment
payment shall at all times be considered a separate and distinct payment as permitted under Code Section 409A. Notwithstanding anything contained in the Plan or in an Award Agreement to the contrary, neither the Company, any member of the
Committee nor any Subsidiary shall have any liability or obligation to any Participant or any other Person for taxes, interest, penalties or fines (including without limitation any of the foregoing resulting from the failure of any Award granted
hereunder to comply with, or be exempt from, Code Section 409A). For purposes of any Award that constitutes “non-qualified deferred compensation” under Code Section 409A, the terms
“termination of employment” or “termination of service” and similar phrases to each shall mean “separation from service” within the meaning of Code Section 409A. 

Section 19. Governing Law. 
 The
validity and construction of the Plan and any Award Agreements entered into hereunder shall be construed and enforced in accordance with the laws of the State of Delaware, but without giving effect to the conflict of laws principles thereof. 

Section 20. Recoupment/Share Ownership. 

Any Award granted pursuant to the Plan (and all Shares acquired thereunder) shall be subject to mandatory repayment and clawback pursuant to
the terms of the Company’s corporate governance guidelines, as in effect from time to time, and as may otherwise be required by law or the rules of any applicable securities exchange. Additional recoupment and clawback policies may be provided
in the Participant’s Award Agreement. In addition, all Awards granted under the Plan (and all Shares acquired hereunder) shall be subject to the holding periods set forth in the Company’s stock ownership guidelines, as in effect from time
to time. 

  
 19 

 Section 21. Effective Date. 

The Plan shall become effective upon the Effective Date. 

[end of Plan] 

  
 20 

 AMENDMENT 1 TO 

BIOATLA, INC. 
 2020 EQUITY
INCENTIVE PLAN 
 Pursuant to the authority reserved to it in Section 9.1 of the BioAtla, Inc. 2020 Equity Incentive Plan, adopted October 29,
2020 and as amended from time to time (the “Plan”), the Board of Directors of BioAtla, Inc. (the “Board”) hereby amends the Plan as follows, effective December 7, 2020: 

1. Section 5.1 of the Plan is hereby amended in its entirety to read as follows: 

“Subject to adjustment as provided in Section 8 hereof and this Section 5, the maximum number of Shares that may be issued
pursuant to Awards under the Plan shall be 4,939,678 Shares (the “Cap”); provided, however, that on January 1st of each year, commencing with the first January 1st following the Effective Date of the Plan, the Cap shall be increased by a number of Shares equal to (x) 4% of the total number of Shares outstanding on the immediately preceding December 31st and (y) such lesser number of Shares determined by the Board. No more than 4,939,678 Shares issued under the Plan may be issued pursuant to the exercise of Incentive Stock Options (provided
that on January 1st of each year of the term of the Plan, this limitation shall be increased by the lesser of (x) 4% of the total number of Shares outstanding on the immediately preceding December
31st and (y) 1,538,461 Shares (subject to adjustment as provided in Section 8 hereof)). The Shares issued under the Plan may, at the election of the Board, be (i) authorized but
previously unissued Shares or (ii) Shares previously issued and outstanding and reacquired by the Company. Notwithstanding the foregoing, Shares issued under Awards granted in assumption, substitution or exchange for previously granted awards
of a company acquired by the Company or any Subsidiary (“Substitute Awards”) shall not count against the Cap, and to the extent permitted by the rules of the stock exchange on which the Shares are then listed or quoted, shares under
a stockholder approved plan of an acquired company (adjusted to reflect the transaction) may be used for Awards under the Plan and do not count against the Cap. No Non-Employee Director may be granted Awards
in any one calendar year covering a number of Shares that have a Fair Market Value on the grant date in excess of (i) $750,000 in the first calendar year of such Non-Employee Director’s initial service as
a Non-Employee Director and (ii) $500,000 in any other calendar year of such Non-Employee Director’s service.” 

2. The reference to “or Inducement Awards” in Section 5.2 of the Plan is hereby deleted. 

3. Clause (iii) in Section 8.1 of the Plan is hereby amended and restated in its entirety to read as follows: 

“(iii) the Cap, the number of Shares set forth in the second clause (y) in Section 5.1 hereof, and the specific Share
limitations under Section 5 hereof and” 

 4. Section 2.11 of the Plan is hereby amended in its entirety to read as follows: 

“‘Effective Date’ means the date that the Plan is approved by the Board, but subject to the approval of the Plan by the
Company’s stockholders within one year after such date.” 
 ***** 

[signature page follows] 

 To record the adoption of this Amendment 1 to the Plan, the Board has caused its authorized officer to
execute this Amendment this 7th day of December 2020. This Amendment 1 to the Plan shall become effective upon its approval by the Company’s stockholders. 

 

			
	BIOATLA, INC.
		
	By:  	 	
		
		 	 /s/ Jay Short

		 	Name: Jay Short
		 	Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]